183550-13-2

Upstream product

• 183551-51-1 3,5-bis(trifluoromethyl)benzyl methanesulfonate 
• 713518-43-5 ethyl 2-cyano-5-(dimethylamino)-3-phenylhexa-2,4-dienoate 
• 183551-60-2 2-chloro-6-methyl-4-phenylnicotinic acid 
• 17277-47-3 (Z)-2-cyano-3-phenylbut-2-enoic acid ethyl ester 
• 32707-89-4 3,5-bis(trifluoromethyl)benzenemethanol 

Downstream Products

• 183550-16-5 4-[3,5-bis(trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-8-methyl-5-oxo-6-phenylpyrido[3,2-f] [1,4]oxazepine 9-oxide 

Relevant academic research and scientific papers

RECEPTOR AGONISTS

The present invention provides a TGR5 receptor agonist comprising a fused ring compound represented by the formula wherein ring A is an optionally substituted aromatic ring; and ring B' is a 5- to 8-membered ring having one or more substituents or a salt

Amide-based atropisomers in tachykinin NK1-receptor antagonists: Synthesis and antagonistic activity of axially chiral N-benzylcarboxamide derivatives of 2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-one

A series of novel N-benzylcarboxamide derivatives of bicyclic compounds, 3,4-dihydropyrido[3,2-f][1,4]oxazepin-5(2H)-one and 2,3,4,5-tetrahydro-6H- pyrido[2,3-b][1,5]oxazocin-6-one, were synthesized by cyclization of N-benzyl-2-chloro-N-(2-hydroxyethyl)-

PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS

An agent for the prophylaxis or treatment of an emotional disorder, which contains the NK-1 receptor antagonist having particular properties of (1) having no serotonin uptake inhibitory effect, (2) being capable of migrating into the hypothalamus, or (3) having an inhibitory effect on micturition reflex, an agent for the prophylaxis or treatment of depression accompanied by urinary frequency, urinary incontinence and/or irritable bowel syndrome, which contains an NK-1 receptor antagonist, an agent for the prophylaxis or treatment of a mood disorder of patients with urinary frequency and urinary incontinence, and a circadian rhythm controller for the hypothalamic endocrine system are provided.

HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE

A compound represented by the formula: wherein ring M is a heterocyclic ring wherein--X=Yis one of--N=C,--CO--N or--CS--N; Ra and Rb are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, with the proviso that at least one of them is an optionally substituted heterocyclic ring; Ring C is an optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted nitrogen-containing heterocyclic ring; and n is an integer from 1 to 6, or a salt thereof has a tachykinin receptor antagonistic activity in vitro, and is useful for preventing or treating depression, anxiety, manic-depressive illness or psychopathy.

CYCLIC COMPOUNDS, THEIR PRODUCTION AND USE

Novel compounds of the following general formula or salts thereof. STR1 wherein Ring M is a heterocyclic ring having--N=C ,--CO--N or--CS--N as the partial structure--X . . . Y ; R. sup.a and R. sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has anexcellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.